| NCT ID | NCT06062394 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,980 participants |
| Start Date | 2024-03-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,980 participants in total. It began in 2024-03-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.
Eligibility Criteria
Inclusion Criteria: * On the Penn Medicine Primary Care Service Line registry * Last 2 Blood Pressure readings with Systolic Blood Pressure \>=140 from any outpatient encounter in the last 12 months AND * ASCVD dx OR ASCVD risk score ≥10% OR Diabetes dx OR A1c ≥6.5 in last year OR Diabetes registry OR Last LDL ≥190 in past five years AND * Not on a statinor PCSK9, Inclisiran OR on a Low-intensity/moderate-intensity statin) with LDL \>100 Exclusion Criteria: * Patients on PCSK9 inhibitors * Documented statin allergy/ or intolerance in the EMR * Pregnancy * Breast feeding * Markedly shortened life expectancy including: 1. metastatic cancer 2. hospice 3. End Stage Renal Disease 4. Congestive Heart Failure 5. Dementia * Is a non-English speaker requiring a translator * Patients who do not have a cell phone
Contact & Investigator
Kevin Volpp, MD, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT06062394 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 80 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06062394 currently recruiting?
Yes, NCT06062394 is actively recruiting participants. Contact the research team at kayla.clark@pennmedicine.upenn.edu for enrollment information.
Where is the NCT06062394 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06062394 clinical trial?
NCT06062394 is sponsored by University of Pennsylvania. The principal investigator is Kevin Volpp, MD, PhD at University of Pennsylvania. The trial plans to enroll 1,980 participants.